Table 6. Logistic regression analyses for autoantibodies in patients with Crohn’s disease.

	Coefficient	Std.Error	Odds ratio	95% CI	P Value
B3
IgG aGP2	0.005	0.002	1.005	1.002, 1.009	0.0044
Gender	0.978	0.430	2.660	1.144, 6.184	0.0230
Severe disease
IgG aGP2	0.011	0.003	1.012	1.005, 1.018	0.0002
IgG ASCA	−0.035	0.020	0.965	0.928, 1.005	0.0822
Age	0.053	0.022	1.055	1.011, 1.100	0.0134
Duration	−0.126	0.061	0.881	0.781, 0.994	0.0397
Steroids response
IgG ASCA	0.015	0.008	1.016	1.001, 1.031	0.0426
5-ASA	1.168	0.364	3.215	1.574, 6.566	0.0013
B2	−0.592	0.355	0.553	0.276, 1.109	0.0953
Duration	−0.088	0.034	0.915	0.857, 0.978	0.0083
Dermatologic
IgA ASCA	0.008	0.004	1.008	1.000, 1.016	0.0461
Anti-TNF	−1.307	0.517	0.271	0.098, 0.746	0.0116

B represents disease behavior (B2, stricturing; B3, penetrating; p, perianal disease modifier) based on the Montreal Classification. 5-ASA, therapy with 5-aminosalicylic acid; aGP2, anti-zymogen granule glycoprotein 2 antibodies; ASCA, anti-Saccharomyces cerevisiae antibody; Anti-TNF, therapy with anti-TNF; Duration, disease duration; L,location of disease (L1, ileal); age, age at diagnosis;

Significant relationships between one dichotomous dependent variable (various clinical outcomes or treatment variants) and one or more independent variables including aGP2 and ASCA, gender, age, disease duration, surgery are shown (P<0.003 respectively). (only significant correlations are shown).